POS0744 SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE MUSCULOSKELETAL SYMPTOMS: PATIENT REPORTED SYMPTOM IMPACT, TREATMENT PATTERNS AND SATISFACTION WITH CURRENT THERAPY OPTIONS

Background Musculoskeletal (MSK) symptoms affect 50-95% of patients with SLE over their disease course negatively impacting functioning, and quality life (QoL).1 In SLE-UPDATE, a US, cross-sectional, non-interventional online survey adults SLE, half the participants reported active MSK symptoms, including pain or swelling in joints (53%) stiffness (57%).2 The present study evaluated sub-group ‘currently active’ symptoms. Objectives To describe self-reported burden, treatment patterns, satisfaction therapies comparing those versus without Methods This secondary analysis SLE-UPDATE data stratified into non-active group. Participants currently experiencing and/or had Joint Pain NRS > 4 were “active group”. All remaining “non-active Analysis comprised descriptive statistics, mean (standard deviation [SD]) for continuous variables, frequency (percentage [%]) categorical variables. Two-sample t-test to compare scores chi-squared testing proportions used. Results Of participants, 285 group 215 was older (44.3 vs. 40.2 years, <0.001) longer time since diagnosis (12.6 9.2 <0.001). More people fibromyalgia (FM) (45 vs 12%, <0.0001), worse pain, fatigue, QoL (Table 1) suggestive Type 2 non-inflammatory Fewer employed full-time (36.5 62.8%) more on permanent disability (27.0 6.5%). assessed general health (fair poor) last month (53.4 20.4%). “flares” prior 3 months; 44.9 41.9% reporting 1-3 flares, 15.1 5.1% 4-6 8.1 2.3% 7 flares. Table 1. Patient Reported Outcomes Active Non-Active FM Non-FM N=129 N=156 N=26 N=189 Worst NRS, Mean (SD ) 6.5 (1.7)* 4.8 (2.6) 6.9 (1.6)* 6.2 (1.8) 4.0 (2.2) 4.9 (2.6)~ 6.7 4.5 7.1 (1.6) 3.5 (2.0) 4.6 (2.6)* FACIT Fatigue Score, 19.1 (10.8)* 28.1 (11.6) 15.4 (9.5)* 22.1 (10.9) 25.7 (13.8) 28.4 (11.3)~ LupusPRO HRQoL Score 48.9 (20.2)* 64.1 (23.0) 45.5 (18.1)* 51.7 (21.4) 63.0 (23.9) 64.3 (22.9)~ NRS: 0 (none)-10 (worst imaginable); Fatigue: 0-52, higher= less fatigue; LupusPRO: 0-100, better QoL; *p < 0.05; ~ Not significant used anti-malarials (50.9 30.7%), immunosuppressants (37.2 26.5%), methotrexate 3.3%), narcotic analgesics (18.6 10.2%), topicals joint (30.5 10.2%). Interestingly, goals greatest importance both groups reduction fatigue but higher (rated very important by 26.7 18.1%). Lower satisfied steroids (58.0 77.8% <0.01), (65.1 80.7% <0.05), (47.2 85.7% =0.061), belimumab (80 95.5%=0.102). Conclusion Reduction main goal whether they Patients lower QoL, current compared driven only part co-morbid FM. Findings from these analyses suggest there are unmet needs understand manifestations, overlap align patient/physician priorities, improve SLE. References [1]Mahmoud K. Curr Opin Rheumatol 2017;29:486-492 [2]Birt J. Rheum Ther 2021;8:1189-1205 Acknowledgements authors would like thank Lupus Foundation America support design survey. Disclosure Interests Diane L Kamen: None declared, Julie Birt Shareholder of: Eli Lilly & Company, Employee Monica Hadi Grant/research from: Evidera received funding conduct this research, Elizabeth Gibbons Don Bushnell has Ren Yu Laure Delbecque Lilly, Kirstin Griffing Company shareholder, paid employee, Anca Askanase Investigator GSK, AZ, Pfizer, Idorsia,